Antimicrobial susceptibility of lower respiratory tract isolates, England, Wales and Northern Ireland (January 2007–March 2010)
| No. of isolates tested (% susceptible) | ||||||
| Total isolates | Tetracyclines | Co-amoxiclav | Ciprofloxacin | Ampicillin/amoxicillin | Macrolides† | |
| H influenzae | 53 895 | 46 342 (99) | 43 685 (93) | 27 175 (99) | 49 834 (77) | 24 583 (15) |
| S pneumoniae | 16 090 | 12 876 (91) | –* | – | 4919 (97) | 14 800 (87) |
| S aureus | 16 860 | 11 070 (94) | 1603 (78) | 8146 (61) | 1047 (23) | 15 410 (68) |
| MSSA | 12 440 | 8131 (95) | 1230 (100) | 5825 (83) | 836 (28) | 12 230 (79) |
| MRSA | 3458 | 2665 (94) | 359 (5) | 2279 (4) | 204 (2) | 2970 (24) |
| Total | 86 845 | 70 288 (96) | 45 288 (92) | 35 321 (90) | 55 800 (77) | 54 793 (49) |
↵* If benzyl-penicillin is used as a proxy for co-amoxiclav, susceptibility is 95% (based on 13 243 isolates tested).
↵† Combined susceptibility results for azithromycin, erythromycin and clarithromycin.
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.